CRDL (Cardiol Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)


CRDL Cardiol Therapeutics Inc CRDL
34 GF Score
Price $1.04
! 3 Warning Signs
View Full Analysis

What is Cardiol Therapeutics FCF Margin %?

Cardiol Therapeutics CRDL -1.42% 34 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates CRDL with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 958 Drug Manufacturers companies, Cardiol Therapeutics ranks worse than 104384.03% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cardiol Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-5.52 Mil. Cardiol Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Cardiol Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Cardiol Therapeutics's current FCF Yield % is -14.64%.

The historical rank and industry rank for Cardiol Therapeutics's FCF Margin % or its related term are showing as below:


During the past 9 years, the highest FCF Margin % of Cardiol Therapeutics was -29813.92%. The lowest was -29813.92%. And the median was -29813.92%.

CRDL's FCF Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.445
* Ranked among companies with meaningful FCF Margin % only.

Cardiol Therapeutics FCF Margin % Related Terms

Cardiol Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Cardiol Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiol Therapeutics FCF Margin % Chart

Cardiol Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only -29,679.03 0.00 0.00 0.00 0.00

Cardiol Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CRDL vs ZTS: FCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiol Therapeutics FCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cardiol Therapeutics's FCF Margin % falls into.


CRDL
34GF Score
Cardiol Therapeutics Inc CRDL
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiol Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cardiol Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-17.309/0
= %

Cardiol Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-5.515/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Cardiol Therapeutics (CRDL) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cardiol Therapeutics and its competitors. According to the industry distribution chart, Cardiol Therapeutics ranks #999999 out of 958 companies in the Drug Manufacturers industry.
Is Cardiol Therapeutics' FCF Margin % too high?
Cardiol Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Cardiol Therapeutics ranks #999999 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cardiol Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cardiol Therapeutics ranks #999999 out of 958 companies for FCF Margin %. This places Cardiol Therapeutics in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cardiol Therapeutics and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiol Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (CRDL) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Cardiol Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cardiol Therapeutics (CRDL), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiol Therapeutics Business Description

Other Exchanges CT9:GermanyCRDL:Canada
Address 2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
34GF Score

Get the complete analysis for CRDL

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.04
Price